Kevin Matte
liked
Good afternoon, traders. Happy Thursday, July 25th. The market is turning sideways, but big tech is climbing back up after dropping Wednesday: earnings season is hurting stock gains enjoyed so far this year.
My name is Kevin Travers, here are stories from the herd on Wall St today.
$Ford Motor(F.US$ stock is moving 18% lower on Thursday after the company missed analyst EPS estimates for the 2024 fiscal year's second quarter. The co...
My name is Kevin Travers, here are stories from the herd on Wall St today.
$Ford Motor(F.US$ stock is moving 18% lower on Thursday after the company missed analyst EPS estimates for the 2024 fiscal year's second quarter. The co...
![Market Tech like Nvidia, Tesla Climbing Again | Herd on Wall St.](https://1500015405.vod2.myqcloud.com/f7703b98vodtransuse1500015405/b017a6bf1253642701825196822/coverBySnapshot/coverBySnapshot_10_0.jpg)
35
10
Kevin Matte
voted
Good morning, traders. Happy Wednesday, July 24th. Tesla missed earnings Tuesday night, and the stock dropped 11% in early trading Wednesday. The firm reported adjusted earnings of 52C, a share on revenue of $25.5B, lower than the estimated 62C. Based on moomoo data, huge outflows from the stock came from small-value traders. Tesla ripped the Nasdaq lower.
My name is Kevin Travers, and I'm coming to you live for the first time; we were push...
My name is Kevin Travers, and I'm coming to you live for the first time; we were push...
![Tesla Pulls Back Hard as Market Falls | Herd on Wall St.](https://1500015405.vod2.myqcloud.com/f7703b98vodtransuse1500015405/004c62c81253642701755182699/coverBySnapshot/coverBySnapshot_10_0.jpg)
53
11
Kevin Matte
liked
$Jaguar Health(JAGX.US$
Initial Results From Ontarget Study Show That Multicenter, Double-Blind, Placebo-Controlled Pivotal Clinical Trial Did Not Meet Primary Endpoint
Jaguar Health (NASDAQ:JAGX) announced results from its Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. The trial did not meet its primary endpoint across all tumor types. However, it revealed clinically relevant signals for crofeleme...
Initial Results From Ontarget Study Show That Multicenter, Double-Blind, Placebo-Controlled Pivotal Clinical Trial Did Not Meet Primary Endpoint
Jaguar Health (NASDAQ:JAGX) announced results from its Phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy. The trial did not meet its primary endpoint across all tumor types. However, it revealed clinically relevant signals for crofeleme...
2
Kevin Matte
liked
Happy Tuesday, July 23. Earnings are flying, Biden has dropped out, and the news team is headed to Wall Street later today to check out the bull and stock exchange; I'll update you with pictures tomorrow.
Here are updates from stories on Wall Street:
$United Parcel Service(UPS.US$ fell 12%, at one point the lowest decline for the stock in one day since 2008, after the company trimmed its revenue outlook for the...
Here are updates from stories on Wall Street:
$United Parcel Service(UPS.US$ fell 12%, at one point the lowest decline for the stock in one day since 2008, after the company trimmed its revenue outlook for the...
![Tesla, Google Earnings are Here, Market Mixed Watching Q2 Results | Herd on Wall St](https://1500015405.vod2.myqcloud.com/57f4fa2avodtransusw1500015405/ef9e66da1253642700772208364/coverBySnapshot/coverBySnapshot_10_0.jpg)
20
9
Kevin Matte
liked
$MicroCloud Hologram(HOLO.US$ going for round 2
3
Kevin Matte
liked
2
14